


CLAIMS

1. A compound having Formula I



Formula I


or a pharmaceutically acceptable salt thereof wherein

R^1 is pyrid-2-yl, isoquinolin-1-yl or 1H-pyrrolo[2,3-c]pyridin-7-yl;

R^1 is optionally mono- or di-substituted with chloro or (C₁-C₄)alkyl;

X and Y are independently either N or C(H), provided that at least one of X or Y is C(H);

R^2 is H, fluoro, hydroxyl or methyl; R^3 is



wherein R^6 and R^8 are each independently H, methyl, halo or (C₁-C₄)alkoxy, provided that only one of R^6 and R^8 is halo;

wherein R^{10} and R^{11} are each independently H, (C₁-C₄)alkyl or (C₃-C₅)cycloalkyl; and


wherein R^7 is hydroxyl, (C₁-C₄)alkoxy, (C₁-C₄)alkoxycarbonyloxy(C₁-C₄)alkoxy, or (C₁-C₄)alkylcarbonyloxy(C₁-C₄)alkoxy.

2. The compound of claim 1 wherein R^1 is pyrid-2-yl and the piperidiny C* is the *R* configuration.

3. The compound of claim 2 wherein X and Y are both C(H), R^2 is H and R^1 is optionally mono-substituted with chloro or methyl.

4. The compound of claim 3 wherein


R^3 is




R^7 is hydroxyl, (C_1-C_2) alkyloxy or

R^{10} is methyl; and


R^{11} is H.



5. The compound of claim 3 wherein R^3 is



6. The compound of claim 3 wherein R^3 is




R^6 is H or methyl and R^8 is H.

7. The compound of claim 1 wherein R^1 isoquinolin-1-yl, and the piperidiny C^* is the *R* configuration.

8. The compound of claim 7 wherein X and Y are both C(H), R^2 is H, hydroxyl, or methyl and R^1 is optionally mono-substituted with chloro or methyl.


9. The compound of claim 8 wherein R³ is




R⁷ is hydroxyl, (C₁-C₂)alkyloxy or

R¹⁰ is methyl; and


R¹¹ is H.



10. The compound of claim 8 wherein R³ is



11. The compound of claim 8 wherein R³ is




R⁶ is H or methyl and R⁸ is H.

12. The compound of claim 1 wherein R¹ is 1H-pyrrolo[2,3-c]pyridin-7-yl,
and the piperidinyl C* is the *R* configuration.

13. The compound of claim 12 wherein wherein X and Y are both C(H), R² is H, hydroxyl,
or methyl and R¹ is optionally mono-substituted with chloro or methyl.


14. The compound of claim 13 wherein R³ is




R⁷ is hydroxyl, (C₁-C₂)alkyloxy or

R¹⁰ is methyl; and


R¹¹ is H.



15. The compound of claim 13 wherein R³ is



16. The compound of claim 13 wherein R³ is



and R⁶ is H or methyl and R⁸ is H.

17. The compound

N-(3-methylpyridin-2-yl)-N-[(3R)-piperidin-3-yl]-4-(pyrazolo[1,5-a]pyrimidin-3-yl)benzamide;

N-(3-chloropyridin-2-yl)-N-[(3R)-piperidin-3-yl]-4-(pyrazolo[1,5-a]pyrimidin-3-yl)benzamide

N-(3-chloropyridin-2-yl)-4-(6-methyl-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-N-[(3R)-piperidin-3-yl]benzamide;

4-(4-{isoquinolin-1-yl}[(3R)-piperidin-3-yl]carbamoyl)phenyl)-1-methyl-1H-pyrazole-5-carboxylic acid;

N-(3-chloropyridin-2-yl)-N-[(3R)-piperidin-3-yl]-5-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)pyridine-2-carboxamide;

ethyl 4-(4-{(3-chloropyridin-2-yl)}[(3R)-piperidin-3-yl]carbamoyl)phenyl)-1-methyl-1H-pyrazole-5-carboxylate;

4-(4-{(3-chloropyridin-2-yl)}[(3R)-piperidin-3-yl]carbamoyl)phenyl)-1-methyl-1H-pyrazole-5-carboxylic acid;

4-(4-((3-chloropyridin-2-yl)[piperidin-3-yl]carbamoyl)phenyl)-1-methyl-1H-pyrazole-5-carboxylic acid;
 1-[(ethoxycarbonyl)oxy]ethyl 4-(4-((3-chloropyridin-2-yl)[piperidin-3-yl]carbamoyl)phenyl)-1-methyl-1H-pyrazole-5-carboxylate;
 1-[(ethoxycarbonyl)oxy]ethyl 4-(4-((3-chloropyridin-2-yl)[(3R)-piperidin-3-yl]carbamoyl)phenyl)-1-methyl-1H-pyrazole-5-carboxylate;
 (1R)-1-[(ethoxycarbonyl)oxy]ethyl 4-(4-((3-chloropyridin-2-yl)[(3R)-piperidin-3-yl]carbamoyl)phenyl)-1-methyl-1H-pyrazole-5-carboxylate;
 (1S)-1-[(ethoxycarbonyl)oxy]ethyl 4-(4-((3-chloropyridin-2-yl)[(3R)-piperidin-3-yl]carbamoyl)phenyl)-1-methyl-1H-pyrazole-5-carboxylate; or
 N-(3-chloropyridin-2-yl)-N-[(3R)-piperidin-3-yl]-4-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)benzamide;
 or a pharmaceutically acceptable salt of any of said compounds.

18. The compound

N-(3-chloropyridin-2-yl)-5-(6-methyl-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-N-[(3R)-piperidin-3-yl]pyridine-2-carboxamide;
 methyl 4-(4-((3-chloropyridin-2-yl)[(3R)-piperidin-3-yl]carbamoyl)phenyl)-1-methyl-1H-pyrazole-5-carboxylate;
 1-[(ethoxycarbonyl)oxy]ethyl 4-(4-((isoquinolin-1-yl)[(3R)-piperidin-3-yl]carbamoyl)phenyl)-1-methyl-1H-pyrazole-5-carboxylate;
 1-methyl-4-(4-((1-methyl-1H-pyrrolo[2,3-c]pyridin-7-yl)[(3R)-piperidin-3-yl]carbamoyl)phenyl)-1H-pyrazole-5-carboxylic acid;
 methyl 1-methyl-4-(4-((3-methylpyridin-2-yl)[(3R)-piperidin-3-yl]carbamoyl)phenyl)-1H-pyrazole-5-carboxylate; or
 1-[(ethoxycarbonyl)oxy]ethyl 1-methyl-4-(4-((1-methyl-1H-pyrrolo[2,3-c]pyridin-7-yl)[(3R)-piperidin-3-yl]carbamoyl)phenyl)-1H-pyrazole-5-carboxylate; or
 a pharmaceutically acceptable salt of any of said compounds.


19. A pharmaceutical composition which comprises a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt of said compound and a pharmaceutically acceptable carrier, vehicle or diluent.

20. A pharmaceutical combination composition comprising: a therapeutically effective amount of a composition comprising

a first compound, said first compound being a compound of claim 1 or a pharmaceutically acceptable salt of said compound;

a second compound, said second compound being a lipase inhibitor, an HMG-CoA reductase inhibitor, an HMG-CoA synthase inhibitor, an HMG-CoA reductase gene expression inhibitor, an HMG-CoA synthase gene expression inhibitor, an MTP/Apo B secretion inhibitor, a CETP inhibitor, a bile acid absorption inhibitor, a cholesterol absorption inhibitor, a cholesterol synthesis inhibitor, a squalene synthetase inhibitor, a squalene epoxidase inhibitor, a squalene cyclase inhibitor, a combined squalene epoxidase/squalene cyclase inhibitor, a fibrate, niacin, a combination of niacin and lovastatin, an ion-exchange resin, an antioxidant, an ACAT inhibitor or a bile acid sequestrant, or a pharmaceutically acceptable salt of said compound; and a pharmaceutically acceptable carrier, vehicle or diluents.

21. A compound having Formula II



Formula II

or a pharmaceutically acceptable salt thereof wherein


R¹ is pyrid-2-yl, isoquinolin-1-yl or 1H-pyrrolo[2,3-c]pyridin-7-yl;

R¹ is optionally mono- or di-substituted with chloro or (C₁-C₄)alkyl;

X and Y are independently either N or C(H), provided that at least one of X or Y is C(H);

R² is H, fluoro, hydroxyl or methyl;

R³ is



wherein R⁶ and R⁸ are each independently H, methyl, halo or (C₁-C₄)alkyloxy, provided that only one of R⁶ and R⁸ is halo;

wherein R¹⁰ and R¹¹ are each independently H, (C₁-C₄)alkyl or (C₃-C₅)cycloalkyl; wherein R⁷ is hydroxyl, (C₁-C₄)alkyloxy, (C₁-C₄)alkoxycarbonyloxy(C₁-C₄)alkyloxy, or (C₁-C₄)alkylcarbonyloxy(C₁-C₄)alkoxy;

R¹³ is H, (C₁-C₄)alkyl, (C₁-C₄)alkylcarbonyloxy(C₁-C₄)alkyl or (C₁-C₄)alkoxycarbonyloxy(C₁-C₄)alkyl;

R¹⁴ is H, (C₁-C₄)alkyl, (C₁-C₄)alkylcarbonyloxy(C₁-C₄)alkyl or (C₁-C₄)alkoxycarbonyloxy(C₁-C₄)alkyl;

R¹⁵ is hydroxyl, tetrazolyl, (C₁-C₂)alkylsulfonyl or trifluoromethylsulfonyl, and

R¹⁶ is H, (C₁-C₄)alkyl, (C₁-C₄)alkylcarbonyloxy(C₁-C₄)alkyl or (C₁-C₄)alkoxycarbonyloxy(C₁-C₄)alkyl.

22. The compound of claim 21 wherein


R¹ is pyrid-2-yl optionally mono-substituted with chloro or methyl;

the piperidiny C* is the *R* configuration;

X and Y are both C(H);

R² is H;

R³ is



R¹⁰ is methyl;

R¹¹ is H; and

R¹³ is (C₁-C₄)alkylcarbonyloxy(C₁-C₄)alkyl.


23. The compound of claim 21 wherein

R¹ is pyrid-2-yl optionally mono-substituted with chloro or methyl;

the piperidinyl C* is the *R* configuration;

X and Y are both C(H);

R² is H; and



24. A compound, which is

4-(4-((3-chloropyridin-2-yl)[(3*R*)-piperidin-3-yl]carbamoyl)phenyl)-1-methyl-N-

[(trifluoromethyl)sulfonyl]-1*H*-pyrazole-5-carboxamide;

N-(3-chloropyridin-2-yl)-4-[1-methyl-5-(2*H*-tetrazol-5-yl)-1*H*-pyrazol-4-yl]-N-[(3*R*)-piperidin-3-yl]benzamide;

1-methyl-4-(4-((3-methylpyridin-2-yl)[(3*R*)-piperidin-3-yl]carbamoyl)phenyl)-N-

(methylsulfonyl)-1*H*-pyrazole-5-carboxamide;


N-(3-methylpyridin-2-yl)-4-[1-methyl-5-(2*H*-tetrazol-5-yl)-1*H*-pyrazol-4-yl]-N-[(3*R*)-piperidin-3-yl]benzamide; or

ethyl 1-[[[1-methyl-4-(4-((3-methylpyridin-2-yl)[(3*R*)-piperidin-3-yl]carbamoyl)phenyl)-1*H*-pyrazol-5-yl]carbonyl](methylsulfonyl)amino]ethyl carbonate;

or a pharmaceutically acceptable salt of any of said compounds.


25. A compound, which is
 ethyl 1-{5-[1-methyl-4-(4-{{(3-methylpyridin-2-yl)}[(3R)-piperidin-3-yl]carbamoyl}phenyl)-1H-pyrazol-5-yl]-1H-tetrazol-1-yl}ethyl carbonate;
 ethyl (1S)-1-{5-[1-methyl-4-(4-{{(3-methylpyridin-2-yl)}[(3R)-piperidin-3-yl]carbamoyl}phenyl)-1H-pyrazol-5-yl]-2H-tetrazol-2-yl}ethyl carbonate; or
 ethyl (1R)-1-{5-[1-methyl-4-(4-{{(3-methylpyridin-2-yl)}[(3R)-piperidin-3-yl]carbamoyl}phenyl)-1H-pyrazol-5-yl]-2H-tetrazol-2-yl}ethyl carbonate;
 or a pharmaceutically acceptable salt of any of said compounds.

26. A compound, which is
 (1-{5-[1-methyl-4-(4-{{(3-methylpyridin-2-yl)}[(3R)-piperidin-3-yl]carbamoyl}phenyl)-1H-pyrazol-5-yl]-2H-tetrazol-2-yl}ethyl 2-methylpropanoate (Diastereomer B; Example 51)



or

2-methyl-1-{5-[1-methyl-4-(4-{(3-methylpyridin-2-yl)[(3R)-piperidin-3-yl]carbonyl}phenyl)-1H-pyrazol-5-yl]-2H-tetrazol-2-yl}propyl 2-methylpropanoate



or a pharmaceutically acceptable salt of any of said compounds.

27. A pharmaceutical composition which comprises a therapeutically effective amount of a compound of claim 21 or a pharmaceutically acceptable salt of said compound and a pharmaceutically acceptable carrier, vehicle or diluent.

28. A pharmaceutical combination composition comprising: a therapeutically effective amount of a composition comprising

a first compound, said first compound being a compound of claim 21 or a pharmaceutically acceptable salt of said compound;

a second compound, said second compound being a lipase inhibitor, an HMG-CoA reductase inhibitor, an HMG-CoA synthase inhibitor, an HMG-CoA reductase gene expression inhibitor, an HMG-CoA synthase gene expression inhibitor, an MTP/Apo B secretion inhibitor, a CETP inhibitor, a bile acid absorption inhibitor, a cholesterol absorption inhibitor, a cholesterol synthesis inhibitor, a squalene synthetase inhibitor, a squalene epoxidase inhibitor, a squalene cyclase inhibitor, a combined squalene epoxidase/squalene cyclase inhibitor, a fibrate, niacin, a combination of niacin and lovastatin, an ion-exchange resin, an antioxidant, an ACAT inhibitor or a bile acid

sequestrant, or a pharmaceutically acceptable salt of said compound; and a pharmaceutically acceptable carrier, vehicle or diluents.